Verrica Pharmaceuticals Inc. - Common Stock (VRCA)
0.8552
+0.00 (0.00%)
NASDAQ · Last Trade: Jul 18th, 7:57 AM EDT
Via Benzinga · July 17, 2025
Via Benzinga · July 7, 2025
Via Benzinga · July 1, 2025
Via Benzinga · April 25, 2025
Via Benzinga · April 4, 2025

Via Benzinga · November 6, 2024

Via Benzinga · November 5, 2024

Via Benzinga · November 5, 2024

Via Benzinga · November 5, 2024

Via Benzinga · November 5, 2024

Via Benzinga · November 5, 2024

Via Benzinga · November 4, 2024

Via Benzinga · October 7, 2024

Via Benzinga · October 3, 2024

Via Benzinga · October 3, 2024

Via Benzinga · August 27, 2024

Via Benzinga · August 14, 2024

Via Benzinga · August 14, 2024

VRCA stock results show that Verrica Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 14, 2024

Via Benzinga · August 14, 2024

Verrica Pharmaceuticals shares positive preliminary results from Part 2 of its Phase 2 trial for VP-315 in treating basal cell carcinoma, showing promising tumor reduction and safety. No serious adverse events reported.
Via Benzinga · August 14, 2024